| Autor: |
Gounder M; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, NY 10021, USA., Abdul Razak AR; Toronto Sarcoma Program, Princess Margaret Cancer Centre, Toronto, ON, M5G 2C1, Canada., Gilligan AM; Karyopharm Therapeutics, Newton, MA 02459, USA., Leong H; Karyopharm Therapeutics, Newton, MA 02459, USA., Ma X; Karyopharm Therapeutics, Newton, MA 02459, USA., Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Chawla SP; Sarcoma Oncology Center, Santa Monica, CA 90403, USA., Martin-Broto J; Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Virgen del Rocio University Hospital, Calle Antonio Maura Montaner, 41013, Sevilla, Spain., Grignani G; Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo (TO), Italy., Schuetze SM; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109, USA., Vincenzi B; Policlinico Universitario Campus, Bio-Medico, Via Álvaro del Portillo, 200, 00128, Roma, Italy., Wagner AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Chmielowski B; Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90024, USA., Jones RL; The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, London, SM2 5PT, UK., Shah J; Karyopharm Therapeutics, Newton, MA 02459, USA., Shacham S; Karyopharm Therapeutics, Newton, MA 02459, USA., Kauffman M; Karyopharm Therapeutics, Newton, MA 02459, USA., Riedel RF; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA., Attia S; Department of Internal Medicine, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. |
